In late age-related macular degeneration (AMD), vision deficits are noticeable, are often debilitating, and can be a precursor to blindness. The availability of vascular endothelial growth factor (VEGF) inhibitor therapies delivered via intravitreal (IVT) injection has revolutionized the treatment of the wet form of late AMD (wet AMD), in that the majority of drug-treated patients are now able to maintain visual acuity and may even experience visual acuity gains. Current branded VEGF inhibitors will continue to dominate wet AMD treatment through the end of the 2015-2025 forecast period, but their patient share will be impacted by the anticipated launch of two emerging anti-VEGF therapies, RTH-258 and abicipar pegol, which may offer increased dosing intervals. In addition, we forecast the launch of biosimilar versions of Lucentis and Eylea in the major markets under study, and these biosimilars will capture patient share from currently available branded therapies as well as potentially impact the uptake of emerging VEGF inhibitors. At present, the wet AMD treatment algorithm is largely limited to monotherapy; however, the adjunctive platelet-derived growth factor (PDGF) inhibitors Fovista and squalamine are expected to launch during the forecast period and will increase overall sales in the market. In contrast to wet AMD, late dry AMD (geographic atrophy [GA]) has no approved therapies. The anticipated launch and subsequent uptake of the first-to-market GA therapy, lampalizumab, during the study period is expected to have a dramatic effect on the AMD market, resulting in increases in the drug-treated patient population and sales.